Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine
| Autor: | Patricia M. Pinto, Mônica Magno Vilar, Miriam Tendler, Gabriel Limaverde-Sousa, Marilia S. Almeida |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Sanitation 030231 tropical medicine lcsh:Medicine Schistosomiasis Review Disease 03 medical and health sciences 0302 clinical medicine Environmental health schistosomiasis vaccine medicine Social inequality Sm14 FABP General Immunology and Microbiology Poverty business.industry Transmission (medicine) lcsh:R Public Health Environmental and Occupational Health Schistosomiasis vaccine medicine.disease Clinical trial 030104 developmental biology Infectious Diseases business medicine.drug biotechnology |
| Zdroj: | Tropical Medicine and Infectious Disease, Vol 3, Iss 4, p 121 (2018) Tropical Medicine and Infectious Disease |
| ISSN: | 2414-6366 |
| DOI: | 10.0334/v1 |
| Popis: | Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequalities, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although schistosomiasis control approach has shown that chemotherapy is capable of reducing morbidity in humans, rapid re-infection is a reminder that the impact of drug treatment on transmission control or elimination initiatives is marginal. In addition, and regardless of more than two decades of well-executed control activities based on large-scale chemotherapy, the disease is expanding in many areas including Brazil. The development of the Sm14/GLA-SE schistosomiasis vaccine is an emblematic open knowledge innovation that has successfully completed Phase I and Phase IIa clinical trials, with Phase II/III trials underway in the African continent and to be followed in Brazil. Discovery and experimental phases were long term achievements leading to a robust collection of data that are strongly supporting the presently ongoing Clinical Phase. This paper reviews the development of the Sm14 vaccine formulated with GLA-SE (Glucopyranosyl Lipid A), from the earlier experimental developments to clinical trials including the recent status of Phase II studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|